



Genetic Insights into *Plasmodium falciparum* Resistance to Sulfadoxine-pyrimethamine through a Study of the 540-dihydropteroate Synthetase Gene Mutations in Jos, Nigeria

Nelson J. Nwankwo ^a, Joel Paul ^a,
Shangshikmwa K. Gaknung ^a, Timloh Fakdul ^a,
Mercy O. Simon ^a, Dinci T. Davou ^b, Mary M. Mankilik ^a,
Richard J. Kutshik ^a, Bitrus Yakubu ^b
and Ishaya Y. Longdet ^{a*}

^a Department of Biochemistry, University of Jos, Plateau State, Nigeria.

^b Department of Biotechnology and Drug Development, NVRI, Plateau State, Nigeria.

Authors' contributions

This work was carried out in collaboration among all authors. Authors IYL, RJK and NJN were responsible for the study design. Authors NJN, JP, MOS, SKG, TF, MMM and DTD conducted the laboratory investigations. Author NJN wrote the initial draft of the manuscript. Authors IYL, BY and RJK supervised the work and contributed to manuscript editing. All authors have reviewed, revised, and ultimately approved the final manuscript for publication.

Article Information

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/110443>

Original Research Article

Received: 23/10/2023

Accepted: 27/12/2023

Published: 31/05/2024

*Corresponding author: E-mail: longdeti@unijos.edu.ng;

Cite as: Nwankwo, N. J., Paul, J., Gaknung, S. K., Fakdul, T., Simon, M. O., Davou, D. T., Mankilik, M. M., Kutshik, R. J., Yakubu, B., & Longdet, I. Y. (2024). Genetic Insights into *Plasmodium falciparum* Resistance to Sulfadoxine-pyrimethamine through a Study of the 540-dihydropteroate Synthetase Gene Mutations in Jos, Nigeria. *Asian Journal of Biotechnology and Genetic Engineering*, 7(1), 128–138. Retrieved from <https://journalajbge.com/index.php/AJBGE/article/view/131>

ABSTRACT

Aim: This study investigates mutations at codon 540 in the dihydropteroate synthetase (540dhps) gene that may confer resistance to sulfadoxine-pyrimethamine treatment by *Plasmodium falciparum* in Jos.

Study Design: The research employs a cross-sectional study design.

Place and Duration of Study: Samples were collected in Jos, Plateau State, Nigeria, from October 2019 to January 2021.

Methodology: One hundred malaria cases underwent assessment, and parasite DNA was extracted from whole blood samples using Zymo extraction kits. PCR and gel electrophoresis identified the Plasmodium genus and *P. falciparum*, along with the 540dhps gene. Sanger sequencing and bioinformatics analyses were performed.

Results: About 50% of the collected samples were positive for the Plasmodium genus, with *P. falciparum* in 96% of cases. About 16% of *P. falciparum* samples were successfully amplified for the 540dhps gene. A silent point mutation was discovered at position 10 of the nucleotide sequence of the 540dhps gene which did not result in amino acid changes.

Conclusion: The study highlights the predominant presence of *Plasmodium falciparum* in Jos, with a substantial 96% prevalence among malaria patients. Unlike the previously reported mutations at codon K540E on the 540dhps gene from other studies, the observed mutation on the nucleotide sequence did not affect the amino acid sequence. Thus, the observed mutation may not be associated with resistance to sulfadoxine-pyrimethamine drugs.

Keywords: Malaria; drug-resistance; single-nucleotide polymorphism; *Plasmodium falciparum*.

1. INTRODUCTION

Malaria remains one of the leading causes of illnesses and deaths globally, surpassing other infectious diseases such as tuberculosis and HIV [1]. In 2020, this widespread parasitic disease affected approximately 241 million individuals, resulting in around 627,000 avoidable deaths [2]. The African continent bears the greatest burden, accounting for approximately 96% of malaria mortality, with about 80% of these deaths occurring in children under five, equating to nearly 750 daily fatalities [3].

The World Health Organization defines severe falciparum malaria as the presence of *Plasmodium falciparum* parasitaemia alongside clinical or laboratory characteristics without other explanatory causes [4]. Around 30 million pregnant women in sub-Saharan Africa face malaria risk [5], with an estimated prevalence of around 28%. Consequently, *Plasmodium falciparum* malaria persists as a major public health issue in the region [6], as human malaria parasites develop resistance to medications [7]. Many countries have switched first-line treatment from chloroquine to sulfadoxine-pyrimethamine due to spreading chloroquine resistance and rising clinical failure rates [8]. However, it is important to know that the sulfadoxine-pyrimethamine drug works by jointly inhibiting the malaria parasites' folic acid production through the enzymes DHPS and DHFR [9].

It is also important to note that the resistance to sulfadoxine-pyrimethamine drugs has been traced to polymorphisms in the DHPS and DHFR genes respectively [7]. Also, the advent of the major East African sulfadoxine-pyrimethamine treatment failures was presaged by the discovery of a DHPS double mutant A437G + K540E [10]. It was also reported that the mutations at five DHPS amino acid sites drive changes to the *Plasmodium falciparum* sulfadoxine binding site, beginning with A437G, followed by S436A, K540E, A581G, and A613S/T, progressively elevating drug resistance [10]. The distinct *Plasmodium falciparum* DHPS (540dhps) mutant alleles have produced varying sulfadoxine resistance levels globally [11]. Moreover, the accumulation of PFDHFR and 540dhps mutations in vivo has also raised concerns about sulfadoxine-pyrimethamine resistance [12].

To effectively control and prevent malaria, it's important to customize strategies based on the local situation, considering factors like disease patterns, available resources, and local commitment [13,14,15]. Research on the genetic variations in the Plasmodium parasite can help improve both current and future antimalarial treatments. That's why we are seeking to understand the specific genetic changes in the 540dhps gene among Nigerian malaria patients in Jos who are resistant to sulfadoxine-pyrimethamine [16,17]. Thus, this research aims

to provide valuable information to support the ongoing efforts to control malaria.

2. MATERIALS AND METHODS

All procedures conducted in this investigation adhered to the guidelines and regulations stipulated by the institutional review board and ethical committee.

2.1 Sample Collection

One hundred malarial samples testing positive for 2 plus and above were obtained in EDTA bottles from Plateau State Specialist Hospital and preserved at 4°C for subsequent DNA extraction.

2.2 DNA Extraction

The Zymo Research extraction kits were used to extract the genomic DNA from 100 µL of each whole blood sample collected, following the manufacturer's instructions. After the extraction, 30µl of the extracted DNA was immediately stored at 4°C for current use, while the remaining 40 microliters (40µl) were archived at -20°C for future use. This process was applied uniformly to all 100 blood samples.

2.3 PCR Amplification of Plasmodium Genus and Plasmodium Falciparum

The purified DNA served as a template for amplifying the Plasmodium genus. The amplification targeted the 18S rRNA gene using the forward and reverse primers (rPLU5-5'-CCTGTTGTTGCCTTAAACTTC-3') and (rPLU6-5'-TTAAATTGTTGCAGTTAAAACG-3') [18] with an expected product size of 1100bp. The thermocycling conditions are detailed in [19].

Five microliters (5µl) of the Plasmodium species' amplified product were used for the second round targeting the 18S rRNA gene of *Plasmodium falciparum*, employing forward and reverse primers 5'-TTAAACTGGTTTGGGAAAACCAAATATATT-3' and 5'-ACACAATGAACTCAATCATGACTACCCGTC-3' respectively, with an expected product size of 205bp [18]. The thermocycling conditions are also detailed in [19].

2.4 PCR Identification of 540dhps

Two rounds of PCR (nested PCR) were conducted to amplify the 540 DHPS gene. The nest1 forward and reverse primer sequences

were 5' AACCTAAACGTGCTGTTC 3' and 5' AATTGTGTGATTTGTCCACAA 3' respectively, while the nest2 forward and reverse primer sequences were 5' CCTAAACGTGCTGTTC 3' and 5' TTCGCAAATCCTAATCCAATATC 3' respectively.

2.5 Sequencing and Bioinformatic Analysis of 540 PfDHPS Gene

The Sangar sequencing method at Inqaba Biotec laboratory, Pretoria, South Africa, was employed for sequencing the *Plasmodium falciparum* 540dhps gene. Bioedit software was used for base calling and consensus sequence formation, and NCBI BLAST search tools were used for nucleotide and amino acid sequence similarity search. OmegaX software facilitated sequence alignments.

3. RESULTS AND DISCUSSION

3.1 PCR Results

Figs. 1. to 5 depict gel images of the amplicons resulting from the PCR amplification of the *Plasmodium falciparum* gene. Specifically, Fig. 1. illustrates the PCR products of *Plasmodium falciparum* gene amplification for samples 1 – 20. Successful amplification for the *Plasmodium falciparum* gene with the expected size (205bp) was observed in samples 7, 11, 12, and 14. In contrast, the remaining samples tested negative for *Plasmodium falciparum*.

Figure 2 displays the PCR products derived from the amplification of *Plasmodium falciparum* genes for samples 21 – 40 where *Plasmodium falciparum* was detected in samples 23, 24, 26, 27, 28, 29, 30, 31, 35, 36, 37, 38, and 40, while the remaining samples tested negative. Furthermore, Figure 3 illustrates the PCR products of *Plasmodium falciparum* genes amplified for samples 41 – 60. *Plasmodium falciparum* was identified in samples 41, 42, 43, 49, 50, 53, 54, 55, and 56, while all other samples tested negative. Subsequently, Figure 4 depicts the PCR products of *Plasmodium falciparum* genes amplified for samples 61 – 80. *Plasmodium falciparum* was detected in samples 61, 62, 66, 69, 77, 78, 79, and 80, with all other samples testing negative. Likewise, Figure 5 presents the PCR products of *Plasmodium falciparum* genes amplified for samples 81 – 100, where *Plasmodium falciparum* was identified in samples 82-86, 88, 90- 95, and 97-100. Conversely, the remaining samples tested

negative for *Plasmodium falciparum*. Finally, Figure 6 provides the gel picture of the amplified PCR products of the 540dhps gene. The PCR amplification revealed that samples 26, 27, 28,

30, 41, 56, 62, and 86 were positive for the 540dhps gene when screened with a 100bp ladder, and positive control (+ve control) with a known size of 500bp.




Fig. 1. Gel Image of PCR Products for Samples 1–20 of *Plasmodium falciparum*




Fig. 2. Gel Image of PCR Products for Samples 21-40 of *Plasmodium falciparum*




Fig. 3. Gel Image of PCR Products for Samples 41-60 of *Plasmodium falciparum*




Fig. 4. Gel Image of PCR Products for Samples 61-80 of *Plasmodium falciparum*




Fig. 5. Gel Image of PCR Products for Samples 81-100 of *Plasmodium falciparum*




Fig. 6. Gel Image of PCR Products of *540dhps* gene

3.2 Analysis of Plasmodium Genus, *Plasmodium falciparum*, and *540dhps* Gene

Among the 100 microscopically screened samples obtained from the Hospital, 50 samples (50%) were confirmed positive for the Plasmodium genus using the PCR technique, while the remaining half tested negative, as detailed in Table 1. Subsequent screening of the 50 positive samples revealed that 48 (96%) were positive for *Plasmodium falciparum*, with only 2 (4%) testing negative. Further analysis showed that out of the 48 *Plasmodium falciparum*-positive samples, 8 (16.67%) were detected for the 540DPHS gene, while 40 (83.33%) were negative. These findings align with previous research indicating *Plasmodium falciparum* as the predominant malaria species in Nigeria. Also, the observed 96% prevalence of *Plasmodium falciparum* in positive samples is consistent with earlier studies reporting approximately 85% prevalence in Edo and Lagos [20], and an 80% prevalence using both microscopic and PCR techniques [18]. However, the overall 50% false positive rate for the Plasmodium genus in our study raises concerns regarding the potential misdiagnoses and treatments within Nigerian hospital settings. As highlighted by [21], clinical laboratories are susceptible to diagnostic errors, particularly in the pre-analytical phases. Consequently, half of the samples collected for this study may have been inaccurately reported by the hospital. As noted before, false positive results can lead to unnecessary malaria treatment and heightened medication use,

thereby increasing the risk of drug resistance [22,23]. Therefore, accurate diagnostic techniques are crucial to prevent the administration of antimalarials to patients without true infections. Also, employing more precise testing methods for *Plasmodium falciparum* could enhance treatment accuracy and mitigate the risks associated with incorrect dosing.

3.3 Alignment of Nucleotide Sequences for the *540dhps* Gene

The results obtained from the query-anchored alignment revealed the substitution of thymine with guanine at position 10 of the nucleotide sequence of the *540dhps* gene, as highlighted in yellow in Fig. 7. The nucleotide blast search confirmed sequences with 99.53% query coverage and 98.79% identity, signifying identical characters in each sequence and high similarity to the sequences in the database. This affirms that the extracted *540dhps* gene sequence closely aligns with those in the database.

Although previous research has demonstrated that mutations in the *540dhps* gene can result in sulfadoxine-pyrimethamine resistance [11], the parasite's resistance to this drug combination has been associated with mutations that reduce its binding affinity [14]. The accumulation of *540dhps* mutations also correlates with increased sulfadoxine-pyrimethamine resistance in vivo [24]. However, the observed mutation at the nucleotide level in this study does not appear to confer resistance. Therefore, this mutation indicates that sulfadoxine-pyrimethamine

resistance may not be linked to the variations in the parasites' 540dhps gene, contrary to some earlier research [25].

The NCBI Blast of 540dhps was conducted as a query sequence against sequences with the accession numbers MN373855.1, MN373848.1, MN373846.1, MN373835.1, and MN373834.1, serving as reference sequences. A silent point mutation was identified at position 10 in the 540dhps query sequence compared to homologous reference sequences, where guanine replaced thymine.

3.4 Analysis of Amino Acid Sequences in the 540dhps Gene

Our findings demonstrate that the mutations observed at the nucleotide level in Fig. 7 did not affect the amino acid sequence, as illustrated in

Fig. 8. While some studies indicate that specific mutations in the 540dhps gene can confer resistance to sulfadoxine-pyrimethamine [6,12,14,23], while other studies report a 16.67% prevalence of the K540E mutation [25], however, it was noted that the K540E mutation is less prevalent in West Africa compared to East and South Africa [25,26]. Previous regional studies have reported higher K540E prevalence rates, including 38.5% in Saudi Arabia [27], 22.5% in Lagos, Nigeria [28], and a prevalence of 58.7% in Northeast Nigeria [29]. However, these regional disparities underscore geographic variations in mutation patterns linked to SP resistance. The absence of amino acid changes in this study however, suggests that the observed nucleotide alteration in the nucleotide sequence may not be responsible for resistance to the sulfadoxine-pyrimethamine drug.

540DHPS	2	CCTAAACCGCCTGTTCAAGAATGTTTGAATGATAAATGAAGGTGCTAGTGTATAGAT	61
MN373855.1	1T.C.....A..A.G.....	60
MN373848.1	1T.C.....A..A.G.....	60
MN373846.1	1T.C.....A..A.G.....	60
MN373835.1	1T.C.....A..A.G.....	60
MN373834.1	1T.C.....A..A.G.....	60
540DHPS	62	ATAGGTGGAGAATCCTCTGGTCCTTTTGTATTACCTAATCCAAAAATTAGTGAAGAGAT	121
MN373855.1	61C.....	120
MN373848.1	61C.....	120
MN373846.1	61C.....	120
MN373835.1	61C.....	120
MN373834.1	61C.....	120
540DHPS	122	TTAGTAGTACCTGTATTACAATTATTTCAAAAAGAAATGGAATGATATAAAAAATAAAAT	181
MN373855.1	121	180
MN373848.1	121	180
MN373846.1	121	180
MN373835.1	121	180
MN373834.1	121	180
Query	182	GTTAAATGTGATGCGAAACCAATTATAAGTATGATACAAATTAACATAATGTTTTTAA	241
MN373855.1	181	240
MN373848.1	181	240
MN373846.1	181	240
MN373835.1	181	240
MN373834.1	181	240
540DHPS	242	GAATGTGTTGATAATGATTTAGTTGATATATAAATGATATTAGTGCTTGTACAAATAAT	301
MN373855.1	241	300
MN373848.1	241	300
MN373846.1	241	300
MN373835.1	241	300
MN373834.1	241	300
540DHPS	302	CCAGAAATTATAAAATTATTAACAAAAAACAATCTATAGTGTAGTTCTAATGCAT	361
MN373855.1	301	360
MN373848.1	301	360
MN373846.1	301	360
MN373835.1	301	360
MN373834.1	301	360
540DHPS	362	AAAAGAGGAATCCACATACAATGGATAAACTAACAAATTATGATAATCTAGTTTATGAT	421
MN373855.1	361	420
MN373848.1	361	420
MN373846.1	361	420
MN373835.1	361	420
MN373834.1	361	420
540DHPS	422	ATAAAAAATTTATTAGAACAAAGATTAAATTTCTTGTATTAAATGGAATACCTCGTTAT	481
MN373855.1	421C.....AT	480
MN373848.1	421C.....AT	480
MN373846.1	421C.....AT	480
MN373835.1	421C.....AT	480
MN373834.1	421C.....AT	480
540DHPS	482	AGGATACTATTGATATTGGATTAGGATTGCGAA	516
MN373855.1	481T..A.....A.....G..	515
MN373848.1	481T..A.....A.....G..	515
MN373846.1	481T..A.....A.....G..	515
MN373835.1	481T..A.....A.....G..	515
MN373834.1	481T..A.....A.....G..	515

Fig. 7. Query-anchored alignment views for single-nucleotide polymorphism (SNP) detection

Table 1. Distribution of *Plasmodium* genus, *P. falciparum* and 540dhps

Parameters	<i>Plasmodium</i> Genus	<i>Plasmodium falciparum</i>	540dhps Gene
Total Sample N (%)	100(100)	50(100)	48(100)
Positives n (%)	50(50)	48(96)	8(16.67)
Negative n (%)	50(50)	2(4)	40(83.33)

N represents the total sample size, while *n* denotes the count of samples categorized as either positive or negative, and % signifies the percentage of positive or negative samples

540DHPS	2	PKRAVQRMFEMINEGASVIDIGGESSGPFVIPNPKISERDLVVPVLQLFQKEWNDIKNKI	181
QEQ07522.1	1	...A.....NEG.....S.....	60
QEQ07515.1	1	...A.....NEG.....S.....	60
AQM50543.1	1	...A.....NEG.....A.....	60
QEQ07502.1	1	...A.....NEG.....S.....	60
QEQ07513.1	1	...A.....NEG.....S.....	60
540DHPS	182	VKCDAPPIISIDTINYNVFKECVDNDLVLDILNDISACTNNPEIIKLLKKKNKFKYSVVLHM	361
QEQ07522.1	61	120
QEQ07515.1	61	120
AQM50543.1	61	120
QEQ07502.1	61	120
QEQ07513.1	61	120
540DHPS	362	KRGNPHTMDKLTNYDNLVYDIKNYLEQRLNFLVLNGIPRYRILFDIGLGF	517
QEQ07522.1	121P.Y.I...I.....	172
QEQ07515.1	121P.Y.I...I.....	172
AQM50543.1	121P.Y.I...I.....	172
QEQ07502.1	121P.Y.I...I.....	172
QEQ07513.1	121P.Y.I...I.....	172

Fig. 8. Alignment of amino acid sequences in the 540dhps gene

Utilizing MegaX software, all nucleotide sequences—540dhps, MN373855.1, MN373848.1, MN373846.1, MN373835.1, and MN373834.1—were translated and aligned through NCBI Blast

4. CONCLUSION

Our investigation revealed that *Plasmodium falciparum* stands as the predominant parasite species responsible for malaria infections in humans, making it the most prevalent malaria species in Jos. The identified mutation, observed exclusively at the nucleotide level, does not impact the amino acid sequence. Consequently, this mutation is unlikely to affect the functionality of the protein. Thus, it is plausible that the reported resistance is not linked to a mutation in the 540-dihydropteroate synthetase gene but rather attributed to other factors.

ETHICAL APPROVAL

Ethical clearance, with registration number NHREC/05/01/2010b, was obtained from the Hospital Institutional Review Committee. All experimental procedures strictly adhered to the relevant laws governing the use of human subjects, ensuring ethical compliance throughout the study.

ACKNOWLEDGEMENTS

The authors appreciate the staff of the Biotechnology Department, National Veterinary Research Institute, Vom for their time,

professional supports and advice in ensuring that we have a reproducible result.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Tajebe A, Magoma G, Aemero M, & Kimani F. Detection of mixed infection level of *Plasmodium falciparum* and *plasmodium vivax* by SYBR Green I-based real-Time PCR in North Gondar, north-west Ethiopia. *Malaria Journal*. 2014;13(1),1–8. Available:<https://doi.org/10.1186/1475-2875-13-411>
2. UNICEF. Malaria data; 2021. Available:<https://data.unicef.org/topic/child-health/malaria/>
3. Sondo P, Derra K, Lefevre T, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, Valea I, Sorgho H, Ouedraogo JB, Guiguemde TR, Tinto H. Genetically diverse *Plasmodium falciparum* infections, within-host competition and symptomatic malaria in humans. *Scientific Reports*. 2019;9(1):1–9. Available:<https://doi.org/10.1038/s41598-018-36493-y>
4. Joste V, Maurice L, Bertin G I, Aubouy A, Boumédiène F, Houzé S, Ajzenberg D, Argy N, Massougbdji A, Dossou-Dagba I, Alao MJ, Cot M, Deloron P, Faucher JF. Identification of *Plasmodium falciparum* and host factors associated with cerebral malaria: Description of the protocol for a prospective, case-control study in Benin (NeuroCM). *BMJ Open*. 2019;9(5),1–9. Available:<https://doi.org/10.1136/bmjopen-2018-027378>
5. Moyeh MN, Njimoh DL, Evehe MS, Ali IM, Nji AM, Nkafu DN, Masumbe PN, Barbara A, Ndikum VN, Mbacham WF. Effects of drug policy changes on evolution of molecular markers of *Plasmodium falciparum* resistance to chloroquine, Amodiaquine, and sulfadoxine-pyrimethamine in the south west region of cameroon. *Malar Res Treat*. 2018; 2:7071383. DOI: 10.1155/2018/7071383
6. Baraka V, Ishengoma DS, Fransis F, Minja DTR, Madebe RA, Ngatunga D, Geertruyden JPV. High level Plasmodium sulfadoxine - pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. *Malaria Journal*. 2015;14:439. Available:<https://doi.org/10.1186/s12936-015-0977-8>
7. Menegon M, Pearce RJ, Inojosa WO, Pisani V, Abel PM, Matondo A, Bisoffi Z, Majori G, Ord R, Warhurst DC, Roper C, & Severini C. Monitoring for multidrug-resistant *Plasmodium falciparum* isolates and analysis of pyrimethamine resistance evolution in Uige province, Angola. *Tropical Medicine & International Health*. 2009;14(10):1251–1257. Available:<https://doi.org/10.1111/j.1365-3156.2009.02369.x>
8. Mwanza S, Joshi S, Nambozi M, Chileshe J, Malunga P, Kabuya JBB, Hachizovu S, Manyando, C, Mulenga M, Laufer M. The return of chloroquine-susceptible *Plasmodium falciparum* malaria in Zambia. *Malaria Journal*. 2016;15(584),2–6. Available:<https://doi.org/10.1186/s12936-016-1637-3>
9. Kavishe RA, Kaaya RD, Nag S, Krogsgaard C, Notland JG. Molecular monitoring of *Plasmodium falciparum* super resistance to sulfadoxine – pyrimethamine in Tanzania. *Malaria Journal*. 2016;15:335. Available:<https://doi.org/10.1186/s12936-016-1387-2>
10. Marks F, Evans J, Meyer CG, Browne EN, Flessner C, von Kalckreuth V, Eggelte TA, Horstmann RD, May J. High prevalence of markers for sulfadoxine and pyrimethamine resistance in *Plasmodium falciparum* in the absence of drug pressure in the Ashanti region of Ghana. *Antimicrob Agents Chemother*. 2005;49(3):1101-1105. DOI: 10.1128/AAC.49.3.1101-1105.2005
11. Lumb V, Das MK, Singh N, Dev V, Khan W, & Sharma Y D. Multiple origins of *Plasmodium falciparum* Dihydropteroate synthetase mutant alleles associated with sulfadoxine resistance in India. *Antimicrob Agents Chemother*. 2011;55(6),2813–2817. Available:<https://doi.org/10.1128/AAC.01151-10>
12. Awono-ambe PH. Prevalence of *Plasmodium falciparum* parasites resistant to sulfadoxine/pyrimethamine in pregnant

- women in Yaounde Cameroon: emergence of highly resistant pfdhfr / 540dhps alleles.2015;2566–2571.
Available:<https://doi.org/10.1093/jac/dkv160>
13. Mayxay M, Pukrittayakamee S, Newton PN, White NJ. Mixed-species malaria infections in humans. Trends in Parasitology. 2004; 20(5).
Available:<https://doi.org/10.1016/j.pt.2004.03.006>
 14. Bloland & WHO. Anti-Infective drug resistance surveillance and containment team: Drug resistance in malaria. A background document for the WHO global strategy for containment of antimicrobial resistance. 2001;4:27,
Available:<https://apps.who.int/iris/handle/10665/66847>. Accessed November 18, 2019.
 15. Iwalokun BA, Iwalokun SO, Adebodun V, Balogun M. Carriage of mutant dihydrofolate reductase and dihydropteroate synthase genes among *Plasmodium falciparum* Isolates recovered from pregnant women with asymptomatic infection in Lagos, Nigeria. Med Princ Pract. 2015;24:436-443.
DOI: 10.1159/000430987
 16. Plebani Mario. Laboratory-associated and diagnostic errors: A neglected link Diagnosis. 2014;1(1):89-94.
Available:<https://doi.org/10.1515/dx-2013-0030>
 17. Jiang T, Chen J, Fu H. et al. High prevalence of Pfdhfr–540dhps quadruple mutations associated with sulfadoxine–pyrimethamine resistance in *Plasmodium falciparum* isolates from Bioko Island, Equatorial Guinea. Malar J. 2019;18,101.
Available:<https://doi.org/10.1186/s12936-019-2734-x>
 18. Saba S, Akhtar T, Hanif A, Sahar S, Niaz S, Bilal H. Molecular detection of malaria in south punjab with higher proportion of mixed infections. Iranian Journal of Parasitology. 2014;9(1),37–43.
 19. Paul J, Nwankwo NJ, Simon M, et al. Non-synonymous mutations associated with *Plasmodium falciparum* artemisinin resistant gene (Pfk13) in Malaria cases, Jos Nigeria. Journal of Advances in Biology & Biotechnology. 2023;26(10): 28-38.
DOI:10.9734/jabb/2023/v26i10661
 20. Oriero EC, Olukosi AY, Oduwole OA, Djimde A, D'Alessandro U, Meremikwu MM, Amambua-Ngwa A. Seroprevalence and parasite rates of plasmodium malariae in a High malaria transmission setting of Southern, Nigeria. The American Journal of Tropical Medicine and Hygiene, 2020;103(6),2208–2216.
Available:<https://doi.org/10.4269/ajtmh.20-0593>
 21. Oboh MA, Badiane AS, Ntadom G, et al. Molecular identification of plasmodium species responsible for malaria reveals plasmodium vivax isolates in duffy negative individuals from southwestern Nigeria. Malar J. 2018;17,439.
Available:<https://doi.org/10.1186/s12936-018-2588-7>
 22. Muller O. Challenges for control and elimination in the 21st century. Malaria Afri 2011;60:193.
 23. Muller O. Challenges for control and elimination in the 21st century. Malaria Afri 2011;60:193.
 24. Shibeshi MA, Kifle ZD, Atnafie SA. Antimalarial drug resistance and novel targets for antimalarial drug discovery. Infect Drug Resist. 2020;13:4047-4060.
Available:<https://doi.org/10.2147/IDR.S279433>
 25. Alam MT, De Souza DK, Vinayak S, et al. Selective sweeps and genetic lineages of *Plasmodium falciparum* drug-resistant alleles in Ghana. J Infect Dis. 2011; 203:220–227.
 26. Dickson ET, Hyman P Mutation, Silent. Brenner's Encyclopedia of Genetics. 2013;553-555.
Available:<https://doi.org/10.1016/B978-0-12-374984-0.01008-1> (<https://www.sciencedirect.com/science/article/pii/B9780123749840010081>)
 27. Doumbo S, Ongoiba OA, Doumtabé D, et al. Prevalence of *Plasmodium falciparum* , anemia and molecular markers of chloroquine and sulfadoxine-pyrimethamine resistance in delivered women in Fana, Mali (in French). Bull Soc Pathol Exot. 2013;106:188–192.
 28. Gatton ML, Martin LB, Cheng Q. Evolution of resistance to sulfadoxine-pyrimethamine in *Plasmodium falciparum*. PMC Journal. 2004;48(6),2116–2123.
Available:<https://doi.org/10.1128/AAC.48.6.2116>

29. Gosling RD, Cairns ME, Chico RM, Chandramohan D. Intermittent preventive treatment against malaria: an update, Expert Review of Anti-infective Therapy. 2010;8:5,589-606, DOI:10.1586/eri.10.36

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/110443>